Syros Announces Pricing of US$70 Million Concurrent Public Offerings

Syros Pharmaceuticals (NASDAQ:SYRS) has announced it has priced its concurrent underwritten public offering of 8.6 million shares of its common stock and accompanying Class A warrants to purchase up to 1.9 million shares of its common stock for US$7.50 in addition to Class A Warrant and 77 shares of its Series A convertible preferred stock. Overall, gross proceeds will total US$70 million.

As quoted in the press release:

The offerings are expected to close on or about April 9, 2019, subject to customary closing conditions.

Cowen and Piper Jaffray & Co. are acting as joint book-running managers for the offerings. JMP Securities is acting as lead manager and Roth Capital Partners is acting as co-manager.

The securities are being offered by Syros pursuant to a shelf registration statement that was filed with the Securities and Exchange Commission (“SEC”) on July 20, 2017 and declared effective by the SEC on July 31, 2017. The offerings are being made only by means of the prospectuses and prospectus supplements that form a part of the registration statement.

Click here to read the full press release.